drugset / Trial / NCT02549989

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

NCT02549989

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness of LY3023414 in treating the participants type of cancer and to determine the types and severity of side effects caused by treatment with LY3023414.

Timeline

Start
2015-09
Primary completion
2022-03-23
Completion
2022-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Samotolisib Small molecule 200 mg Oral

Indications